CurePSP’s Post

Source: Molecular neurobiology This study investigates the metabolic dysregulations caused by blast-induced trauma in a preclinical animal model. Using advanced metabolomic and statistical bioinformatic platforms, the study identifies significant changes in metabolic markers at different time points post-injury. The study also explores pathway dysregulations and correlation networking, shedding light on the biological mechanisms of blast-induced brain or systemic trauma.

Interested in studying neurological diseases ... make sure to include Hyperion Imaging Mass Cytometry to your workflow 📌 December 22nd, 2023: Bristol Myers Squibb and Karuna Therapeutics "..today announced that they have entered into a definitive merger agreement under which Bristol Myers Squibb has agreed to acquire Karuna..." 📌 December 6th, 2023: AbbVie to Acquire Cerevel Therapeutics in Transformative Transaction to Strengthen Neuroscience Pipeline 📌 November 21st, 2023: "... Merck , and Caraway Therapeutics, Inc. announced today that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Caraway Therapeutics ..." These are some of the top Pharmas Globally that are making a big play in the space of Neurosciences. Attached is a document that highlights the advantages of Tissue Imaging Mass Cytometry with the Hyperion XTi. If you want to gain a deep understanding of your tissue microenvironment at a single cell protein level, the Hyperion Tissue Imaging system must be a part of your workflow. Want to speak about this further, DM me on LinkedIn or email me at zeeshan.farooq@standardbio.com #neuroscience #neurology #neurodegeneration #neuro #imagingmasscytometry #cytof #tme #immunotherapy #immunohistochemistry #spatialbiology #spatialtranscriptomics #pathology links to posts mentioning these transactions in comments

#EditorsChoice 📝 Development of Alzheimer’s Disease Biomarkers: From CSF- to Blood-Based Biomarkers — Mankhong and colleagues. In this paper, the authors aimed to review and discuss different groups of blood-based biomarker candidates for Alzheimer’s disease therapeutics and diagnostics. Full text is available 👇 https://lnkd.in/dCb9WX7Y #medicine #health #research #science #neuroscience

Happy to Share! Our newest research publication,"Network Pharmacology-Based Approach to Elucidate the Pharmacologic Mechanisms of Natural Compounds from Dictyostelium discoideum for Alzheimer's Disease Treatment" has just been published! In this study, our research team delve into the potential of secondary metabolites from Dictyostelium discoideum as multi-target treatments for Alzheimer's disease, using advanced network pharmacology methods. Their findings highlight nearly 50 potential targeting genes and multiple signaling pathways, with a particular focus on the neuroinflammatory pathway mediated by COX-2. For those interested in the detailed mechanisms and potential therapeutic effects of these natural compounds, check out our full article. We're happy to continue this line of research and contribute to the development of more effective AD treatments. Click the below link for the significant step towards understanding how natural compounds can be used more effectively in combating Alzheimer's disease. https://lnkd.in/dBZ-9eJR Authors: Dr. Mukul Jain, Nil Patil, Rupal Dhariwal, Lee Seong Wei, and Airfullah Mohammed Parul University Mukul Jain, PhD Patil Nil 🧠 Rupal Dhariwal #AlzheimersResearch #Pharmacology #Neuroscience #Publication #ResearchImpact #Cellpress #Heliyon #ComputationBiology #NetworkPharmacology #Neuro #NeuroDegeneration

Exciting news in neuroscience diagnostics! Fujirebio Diagnostics, Inc. has launched the Lumipulse G GFAP assay in the US, a groundbreaking tool for researchers studying neurological conditions. This fully automated Chemiluminescent Enzyme Immunoassay (CLEIA) test quantitatively measures glial fibrillary acidic protein (GFAP) in human plasma and serum in just 35 minutes. Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc., states: "We continue our engagement in biomarker-based testing for neurological diseases with the Lumipulse G GFAP, affirming our commitment to play an essential partnering role in both research and clinical routine." This launch further solidifies Fujirebio's position as a leader in neuro biomarker testing, following their 2023 introductions of NfL and pTau 217 assays. https://lnkd.in/euNv5Sat 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. #PracticalPatientCare #Neuroscience #Diagnostics #MedicalInnovation

Save $ on Cell culture soultions for one more month! Our cell culture solutions are designed to optimize cell growth, #viability, and #functionality, helping ensure exceptional #results for your experiments. Until June 30, 2024, use code RNDCC6 to unlock this offer*: Spend $700, get 24% off* Spend $1200, get 31% off* -FBS -plastics #flasks #pipettes #nunc -media & supplements #trypsin #dmem #rpmi #dpbs -growth factors & cytokines #recombinant proteins -stem cell & neurobiology #stemflex #b27 #neurobasal medium -transfection reagents #lipofectamine -advanced cell models #laminin #keratinocyte -cancer research #hplm -gene editing #Cas9 *check out the website linked here for the complete list of eligible products

A compact epigenetic editor to silence brain genes for therapeutics While the field of molecular medicine has made significant progress in recent years, evidenced by a surge in approvals of antisense oligonucleotide (ASO) therapies and the first CRISPR-based treatment, neurodegenerative diseases like prion disease, Huntington's disease, Alzheimer's disease, and Parkinson's disease continue to pose a major challenge. Toxic protein aggregation is believed to play a role in neurodegeneration, suggesting that gene silencing could be a broadly applicable therapeutic approach. However, despite the potential of ASOs and CRISPR-based silencing to suppress the production of pathogenic proteins, these efforts have yet to be successful. Here, researchers described a new Zinc Finger compact epigenetic editor called CHARM that can silence prion protein (PrP) expression in the brains of mice, offering a promising new avenue for treating neurodegenerative diseases. The article, entitled: "Brainwide silencing of prion protein by AAV-mediated delivery of an engineered compact epigenetic editor" was published in Science: https://lnkd.in/eXc-FZMh. #genetics #genomics #precisionmedicine #genomicmedicine #genetherapy #crispr #aso #drugdevelopment #epigenetics #epigenomics #brain #neurology #neuroscience #neurodegeneration #prion #alzheimer #parkinson #als #therapeutics #biotechnology #innovation #research #science #sciencecommunication

☑️ *READ ABSTRACT BELOW:* Keywords: ALS; C9orf72; CP: Neuroscience; GSK2606414; NMO; autophagy; dipeptide repeat proteins; muscle denervation; neural degeneration. Hexanucleotide repeat expansions in the C9orf72 gene are the most common cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia. Due to the lack of trunk neuromuscular organoids (NMOs) from ALS patients' induced pluripotent stem cells (iPSCs), an organoid system was missing to model the trunk spinal neuromuscular neurodegeneration. With the C9orf72 ALS patient-derived iPSCs and isogenic controls, we used an NMO system containing trunk spinal cord neural and peripheral muscular tissues to show that the ALS NMOs could model peripheral defects in ALS, including contraction weakness, neural denervation, and loss of Schwann cells. The neurons and astrocytes in ALS NMOs manifested the RNA foci and dipeptide repeat proteins. Acute treatment with the unfolded protein response inhibitor GSK2606414 increased the glutamatergic muscular contraction 2-fold and reduced the dipeptide repeat protein aggregation and autophagy. This study provides an organoid system for spinal neuromuscular pathologies in ALS and its application for drug testing. Gao C, Cell Rep. 2024 Mar 26;43(3):113892. doi: 10.1016/j.celrep.2024.113892. Epub 2024 Mar 1. PMID: 38431841. #Gesundheit #Bildung #Fuehrung #Coaching #Mindset #Motivation #Gehirn #Neuroscience #Psychologie #Persoenlichkeitsentwicklung #Kindheit #KeyNoteSpeaker #Humangenetik #Biochemie #Neuroleadership #Ernaehrung #Transformation #Stress #Demografie #Gender #Age #interkulturelleKompetenz #Epigenetik #Veraenderung #EmotionaleIntelligenz #Change #Gesellschaft #Organisationsentwicklung #Philosophie #Beratung # Quantum